Luminopia announced today that it received FDA de novo approval for its prescription therapy for improving vision in children with lazy eye.
Cambridge, Massachusetts-based Luminopia’s prescription Luminopia One holds indication for improvement in visual acuity in children between ages four and seven with lazy eye (amblyopia) associated with anisometropia and/or mild strabismus, having received treatment instructions as prescribed by a trained eye-care professional, according to a news release.
Get the full story at our sister site, Medical Design & Outsourcing.